Breaking AI & Tech News Analyzed

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.

The LeadAfter more than a decade of devastating conflict, Syria stands at a critical juncture where the restoration of its healthcare system has become the cornerstone of national recovery. The nation's ability to heal—both physically and psychologically—is inextricably linked to the rebuilding of medical infrastructure that has been systematically destroyed during the war.The Collapsed Medical InfrastructureSyria's healthcare system has suffered catastrophic damage throughout the conflict, with reports indicating that over 70% of hospitals and clinics have been destroyed, damaged, or rendered non-functional. The exodus of medical professionals has left the country with a severe shortage of doctors, nurses, and specialized healthcare workers. Essential medical supplies are consistently scarce, while vaccination programs have collapsed, leading to preventable disease outbreaks in vulnerable populations.The Humanitarian ConsequencesThe absence of adequate healthcare has had devastating effects on Syria's population. Maternal mortality rates have increased by over 200%, while infant mortality has risen to levels not seen in decades. Chronic conditions like diabetes and hypertension go untreated, leading to complications and premature deaths. Mental health services are virtually nonexistent, leaving millions traumatized by years of violence with no access to psychological support or counseling.The Road to RecoveryRebuilding Syria's health system requires a comprehensive approach that addresses immediate needs while establishing long-term sustainability. This includes rehabilitating existing medical facilities, establishing supply chains for essential medicines and equipment, training healthcare workers, and implementing public health initiatives. The process must prioritize primary healthcare services that reach all populations, regardless of geographic location or political affiliation.International Challenges and OpportunitiesThe international community has recognized healthcare as a critical component of Syria's recovery, with numerous organizations pledging support for reconstruction efforts. However, significant challenges remain, including political divisions, funding shortfalls, and security concerns that complicate implementation. Sanctions and restricted access to certain medical supplies further hinder progress. Despite these obstacles, the rebuilding of Syria's healthcare system presents an opportunity for international cooperation and a foundation for broader peace and stability in the region.

What is Immunotherapy? Immunotherapies are biological treatments that harness the immune system to prevent, control and fight diseases and other conditions. The most familiar are vaccines, which train the immune system to recognise targets such as invading pathogens. Other immunotherapies boost immune responses when they are too weak, or dampen them down when they are out of control. Still others draw on engineered immune cells or lab-made antibodies to disrupt disease processes. The Evolution of Immunotherapy Efforts to prevent disease by boosting the immune system date back thousands of years, but advanced therapies for a wide range of illnesses have come to the fore in the past two decades. A global registry of clinical trials listed 1,257 trials of immunotherapies between 2006 and 2016. The figure leapt to 4,591 in the past decade. How Do Cancer Immunotherapies Work? Cancer patients have seen great benefits from immunotherapies and dozens are now approved for more than 30 types of cancer. Some tumours evade the body’s defences by switching off immune cells, but antibody-based drugs – called checkpoint inhibitors – reactivate them so they can recognise and attack the malignancies. The Future of Immunotherapy: Beyond Cancer Researchers are now testing whether existing immunotherapies can help a broader range of patients. This includes treating allergies, infections, brain diseases, and autoimmune disorders. Some of the most exciting new immunotherapies draw on recent Nobel prizewinning work on regulatory T-cells, or Tregs, which can be used to dampen down immune responses. The Potential of Tregs in Immunotherapy Tregs are unusual immune cells that stand the immune system down once the threat has been dealt with. Therapies are in the pipeline for dementia and autoimmune diseases from type 1 diabetes and rheumatoid arthritis to lupus and chronic inflammation. The potential for Tregs is vast, and researchers believe that half of all deaths have a component that is immunological.

Retatrutide Delivers Up to 28% Body‑Weight Reduction in Phase 3 StudyA new weight‑loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight, Eli Lilly announced on Thursday. Phase 3 Trial Design and Dosing RegimenThe Indiana‑based company randomized 2,339 adults with obesity or overweight and at least one weight‑related comorbidity (no diabetes) to receive Retatrutide at 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. The drug is a once‑weekly triple hormone receptor agonist targeting GLP‑1, GIP, and glucagon. Quantitative Outcomes and Safety ProfileAverage weight loss: 70.3 lb (28.3%) at the 12 mg dose.Average loss at 9 mg: 64.4 lb (25.9%).Average loss at 4 mg: 47.2 lb (19.0%).45.3% of 12 mg participants lost ≥30% of body weight.65.3% reduced BMI below 30; 37.5% of those starting with BMI ≥ 40 achieved this.Side‑effects increased with dose: nausea (28.6%‑42.4%), diarrhea (25.2%‑34.1%), vomiting (up to 25%).For comparison, Zepbound yields 15‑20% loss over 72 weeks and Wegovy 14‑19% over 64‑72 weeks. Implications for the Obesity‑Drug LandscapeThe magnitude of loss positions Retatrutide as the most effective pharmacologic option to date, potentially shifting prescriber preference away from existing GLP‑1 monotherapies. Its triple‑agonist mechanism adds glucagon, a hormone absent from current products, which may enhance metabolic control and appetite suppression. Future Outlook: Approval Path and Market PotentialAnalysts expect regulatory submissions within the next year, with a likely U.S. FDA review in 2027. If approved, Retatrutide could capture a sizable share of the rapidly expanding obesity‑treatment market, prompting competitors to explore multi‑agonist formulations.

The Plant That Changed MedicineGoat's rue or French lilac, Galega officinalis, is a wild plant often grown in gardens for its clusters of attractive lilac or white flowers. For centuries, the plant was used to treat diabetes. Its key ingredient was later identified as galegine, which lowers blood glucose levels but has toxic side-effects.From Natural Remedy to Synthetic SolutionEventually, galegine led to the development of the synthetic drug metformin, now the classic treatment for diabetes by controlling blood sugar. Metformin has none of the toxic side effects of galegine and is now one of the most prescribed drugs in the world. For many years, however, metformin was vilified and banned in many countries because of its association with galegine.The Emergence of a Medical MultitaskerMetformin is now becoming something of a super drug for its anti-cancer effects, cardiovascular protection, delaying the onset of diabetes, and helping some people lose weight. It may even lower the risks for cognitive decline, dementia, strokes, slow aging and increase life expectancy.Understanding the MechanismExactly how metformin achieves all these remarkable wonders is not entirely understood, but it is not bad for a drug that originally came from an attractive wild plant. The scientific community continues to research the multiple pathways through which this simple compound derived from a garden plant can have such profound effects on human health.

Breakthrough Eye‑Scan Technology UnveiledResearchers disclosed a novel ocular imaging method that can spot disease markers long before patients experience any symptoms. The announcement, made on 2026‑05‑13, highlights the scan's ability to analyze retinal biomarkers linked to systemic conditions.Mechanism Behind Pre‑Symptomatic DetectionThe scan leverages high‑resolution retinal photography combined with AI‑driven pattern recognition. By mapping micro‑vascular changes and cellular anomalies, the system flags early signs of illnesses such as diabetes, hypertension, and neurodegenerative disorders.Non‑invasive retinal imagingMachine‑learning algorithms trained on longitudinal health dataDetection window extending years before conventional diagnosisPotential Healthcare Cost ImplicationsEarly identification could reduce long‑term treatment expenses by enabling timely interventions. While specific cost figures were not disclosed, analysts note that preventing disease progression typically lowers hospitalization rates and chronic‑care spending.Implications for Preventive MedicineThis technology aligns with a growing emphasis on preventive care, offering clinicians a tool to monitor patient health proactively. It may also reshape screening protocols, shifting focus from reactive testing to routine ocular assessments.Future Outlook for Early DiagnosisExperts anticipate broader clinical trials and integration into primary‑care settings within the next few years. If validated, the eye scan could become a standard component of annual health check‑ups, accelerating the move toward a pre‑emptive healthcare model.

The Global Obesity Landscape: Not a Uniform EpidemicA continuing rise in obesity around the world is not inevitable, research suggests, with rates in some countries levelling off or potentially in decline. Researchers say focusing on what has been described as a global epidemic of obesity hides large variations in trends across different countries, sexes and age groups.Majid Ezzati, a professor of global environmental health at Imperial College London and author of the study, said: "I think the thing that's really important is this diversity exists even across countries that have really similar economic, environmental, technological features. So countries may look the same on the surface of it but obesity looks different."Comprehensive Analysis Reveals Complex PatternsWriting in the journal Nature, the international team, which involved a network of almost 2,000 researchers, described how for each country they calculated the change in the prevalence of obesity each year between 1980 and 2024. They drew on data from 4,050 population-based studies involving 232 million participants aged five years and above.They found that the prevalence of obesity increased in almost all countries over the 45-year period. However, in most high-income countries, a rapid rise in the prevalence of obesity has been replaced by a slower increase, a plateau, or a potential decline.Regional Variations in Obesity PrevalenceThe rate of growth in obesity is slowing in adults in the US and UK, reaching a prevalence of 40-43% and 27-30% respectively in 2024. Obesity is increasing steadily in Finland, has plateaued in Germany and may have started to decline in France, where 24-25%, 20-23% and 11-12% of adults respectively were thought to have the condition in 2024.Slowdowns were often seen in children and adolescents before adults. For the former group, the slowdown started as early as 1990 in Denmark and rates stabilised in most high-income countries by the mid-2000s. Obesity has plateaued in boys and girls in the UK, US, Germany and Japan at prevalences of 10-12%, 20-23%, 7-12% and 3-7% respectively.Meanwhile, obesity among young people and adults in many low-income and middle-income countries continues to rise and in some cases this is accelerating.Understanding the Drivers Behind Divergent TrendsThe team say it is important now to unpick what is behind the trends in different countries. The situation is complex: while there may be shared reasons for obesity, such easy access to unhealthy foods or a decrease in physical activity, the team say country-specific factors rooted in social, economic and policy considerations could also be important, from perceptions around body image to the presence or absence of interventions such as healthy school meals.Naveed Sattar, a professor of metabolic medicine at the University of Glasgow, who was not involved in the work, said the study highlighted how obesity trends were diverging sharply across countries. "English-speaking nations are doing particularly poorly, with the UK now among the countries with the highest obesity levels worldwide," he said.Sattar said it was encouraging that some countries appeared to have reached a plateau in obesity rates. "Understanding what has worked in those settings is crucial as it could help shape more effective public health strategies for the UK," he said, although he noted there could be country-specific aspects or customs at play.Future Outlook and Potential InterventionsHe said the rapid rise in obesity across many developing countries was especially concerning, not least as it could result in increases in diabetes and cardiovascular conditions.He added: "Looking ahead, it will be important to see how wider use of effective weight-loss medicines affects obesity trends, particularly in the UK and the United States. Recent signs of stabilisation in the USA suggest there may be room for cautious optimism. Combining evidence-based medicines with strong public health measures could begin to shift obesity rates in the right direction."

ACCESS: Medicare’s First AI‑Enabled Outcome‑Based Payment Model Pair Team was announced on April 30 as one of 150 organizations accepted into ACCESS (Advancing Chronic Care with Effective, Scalable Solutions), a CMS initiative that launches on July 5. The program shifts reimbursement from traditional time‑based fees to payments tied to measurable health outcomes such as lower blood pressure or reduced pain, covering conditions like diabetes, hypertension, chronic kidney disease, obesity, depression, and anxiety. Revenue Scale and Funding Behind Pair Team Staff: roughly 850 clinical professionals, the largest community‑health workforce in California. Revenue: exceeds nine figures (>$100 million) annually. Capital raised: about $30 million from investors including Kleiner Perkins, Kraft Ventures, and Next Ventures. Patient reach: partnerships give access to ~500,000 potential patients, with a goal of 1 million within three years. Industry context: digital‑health funding hit its highest Q1 total since the pandemic, with AI firms capturing the bulk of new capital. How Outcome‑Based Payments Could Redefine Chronic Care Delivery The ACCESS model creates the first federal mechanism to pay for AI agents that monitor patients between visits, coordinate social services, and ensure medication adherence. Flora, Pair Team’s voice‑AI assistant, now handles 24/7 intake, referrals, and check‑ins, delivering hour‑long conversations that act as both clinical touchpoints and companionship for high‑needs patients. Peer‑reviewed research in the Journal of General Internal Medicine shows Pair Team’s community‑integrated approach cuts avoidable emergency and inpatient utilization, with one‑in‑four hospital visits and one‑in‑two ER visits averted for its members. Risks remain: the program funnels highly sensitive data into a federal system with a history of breaches, and past CMS innovation pilots have drawn criticism for increasing federal spending without delivering projected savings. What’s Next for AI‑First Health Providers Under ACCESS Batlivala argues that lower per‑patient reimbursement rates are intentional, forcing providers to adopt lean, AI‑driven operations. As the program scales, success will hinge on: Automating patient interactions to keep costs below payment thresholds. Demonstrating measurable outcome improvements across the covered chronic conditions. Managing data‑privacy concerns to maintain trust among vulnerable populations. Attracting additional capital as investors watch the first AI‑centric Medicare payment model unfold. If Pair Team and its peers can prove the model’s efficacy, ACCESS could become a template for nationwide AI‑enabled, outcome‑based reimbursement, reshaping how Medicare incentivizes technology in health care.

The New Tool for Obesity-Related Disease Risk A new tool developed by UK researchers can help identify individuals most at risk of obesity-related diseases, such as type 2 diabetes, gout, and stroke. This tool uses a type of AI called interpretable machine learning to analyze data from nearly 200,000 participants of the UK Biobank project. How the Tool Works The researchers applied the AI tool to data from participants with a BMI of 27 or greater, identifying 20 health, lifestyle, and demographic features that could predict the 10-year risk of 18 different obesity-related complications. These features include age, sex, total cholesterol, and creatinine levels. The Data Analysis The team tested the validity of the tool, dubbed Obscore, using UK Biobank data and datasets from two independent health studies. The results showed that participants with the same age, sex, and BMI can have very different risks for various obesity-related conditions. The Impact Analysis The tool could help inform strategies for prioritizing who should receive weight-loss interventions, particularly in cases where access to NHS treatments is limited. According to Prof Nick Wareham, the tool is not about extending the use of particular therapies, but rather about developing and validating a score that can help with more rational resource allocation. The Prediction The researchers believe that their tool could be useful for prioritizing individuals who would benefit most from weight-loss medications. However, Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that substantial further development and validation will be required before such an approach can be translated into routine clinical practice.